Harki to Serve as Co-Investigator and Deputy Director of Medicinal Chemistry and DMPK
May 27, 2022
Minneapolis, Minn
May. 27, 2022
The University of Minnesota has received $66 million from the National Institute of Allergy and Infectious Diseases (NIAID) to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2.
The Midwest Antiviral Drug Discovery (AViDD) Center is part of a network of nine national centers established by NIAID in response to the public health emergency caused by COVID-19.
The hub of the Center is located in Minnesota with two-thirds of the scientists located in the broader Midwest. Dr. Daniel Harki, Northrop Professor in the College of Pharmacy’s Department of Medicinal Chemistry, serves as co-Investigator and Deputy Director of the Medicinal Chemistry and Drug Metabolism and Pharmacokinetics (DMPK) Core.
Read the University’s official press release about the grant and establishment of the center.
Media Contacts
Related Stories
Dr. Melanie Nicol, associate professor and director of graduate studies in the Department of Experimental and Clinical Pharmacology (ECP) received a new award of $3 million across the next five years from the National Institutes of Health (NIH).
Duerfeldt's research is focused on the development of chemical tools that can be utilized to enhance our understanding of disease mechanisms and the development of new therapeutic leads for bacterial infections and ocular diseases.
Assistant professor Ameya Kirtane, PhD, has joined the College of Pharmacy’s Department of Pharmaceutics.